The Clinical Evidence Animal Studies (Compelling Foundation) Multiple animal studies have shown dramatic results: Rat tendon repair (2015 study): BPC-157 treated group: 87% functional recovery by day 14 Control group: 42% functional recovery by day 14 Treated tendons showed superior collagen organization and strength Rat ACL studies: BPC-157 accelerated cruciate ligament healing Improved biomechanical properties of healed tissue Enhanced recovery of motor function Systemic benefits: Improved gastric ulcer healing (origin research) Accelerated bone fracture healing Enhanced wound healing Human Clinical Data (Emerging) While human long-term trials are still limited, preliminary human studies show: Chronic tendinopathy cases: Improvements in pain and function Better ultrasound imaging of tendon structure Return to activity timelines shortened by 30-50% in pilot studies Post-surgical recovery: Athletes returning to training faster Reduced post-operative pain Better functional outcomes in ACL reconstructions (preliminary data) Safety profile: No serious adverse events in human trials to date Well-tolerated across multiple routes of administration No apparent systemic toxicity Important caveat : Human clinical research on BPC-157 is still in early stages

Experiment with one change at a time, track lab results, and choose what suits your life
The oral route of drug delivery is challenging for peptides because the GI tract is specifically designed to break down proteins and peptides into their constituent amino acids for absorption
Furthermore, biomechanics differ significantly in the specific regions of the spine and the different imaging modalities, biomechanical testing measures and histological as well as immunological methods are evolving
Encouragingly, recent developments have begun to address several key translational challenges associated with CQDs [188]
NAD+ IV therapy keeps levels high for 24-72 hours, while glutathione works faster but doesn't last as long and helps detox your body quickly